Nothing Special   »   [go: up one dir, main page]

EA201790236A1 - Антитела против vasa и способы их получения и использования - Google Patents

Антитела против vasa и способы их получения и использования

Info

Publication number
EA201790236A1
EA201790236A1 EA201790236A EA201790236A EA201790236A1 EA 201790236 A1 EA201790236 A1 EA 201790236A1 EA 201790236 A EA201790236 A EA 201790236A EA 201790236 A EA201790236 A EA 201790236A EA 201790236 A1 EA201790236 A1 EA 201790236A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vasa
mabs
methods
production
disclosed
Prior art date
Application number
EA201790236A
Other languages
English (en)
Inventor
Дэвид Т. Уивер
Бо Чжан
Original Assignee
Оувэсайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оувэсайенс, Инк. filed Critical Оувэсайенс, Инк.
Publication of EA201790236A1 publication Critical patent/EA201790236A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Раскрыты антитела (mAb) против VASA, в частности гуманизированные mAb, которые специфично связываются с VASA с высокой аффинностью. Предоставлены аминокислотные последовательности CDR легких цепей и тяжелых цепей, а также консенсусные последовательности для этих CDR этих mAb против VASA. Также раскрытие предусматривает молекулы нуклеиновой кислоты, которые кодируют mAb против VASA, экспрессирующие векторы, клетки-хозяева, способы получения mAb против VASA и способы экспрессии mAb против VASA. Наконец, раскрыты способы использования mAb против VASA для того, чтобы выделять и/или очищать клетки, экспрессирующие VASA.
EA201790236A 2014-09-16 2015-09-16 Антитела против vasa и способы их получения и использования EA201790236A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
EA201790236A1 true EA201790236A1 (ru) 2017-11-30

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790236A EA201790236A1 (ru) 2014-09-16 2015-09-16 Антитела против vasa и способы их получения и использования

Country Status (26)

Country Link
US (4) US9403913B2 (ru)
EP (1) EP3194448A4 (ru)
JP (2) JP2017532953A (ru)
KR (1) KR20170056521A (ru)
CN (1) CN106573985A (ru)
AP (1) AP2017009758A0 (ru)
AU (1) AU2015317813B2 (ru)
BR (1) BR112017003263A2 (ru)
CA (1) CA2959179A1 (ru)
CL (1) CL2017000402A1 (ru)
CO (1) CO2017001724A2 (ru)
CR (1) CR20170067A (ru)
DO (1) DOP2017000050A (ru)
EA (1) EA201790236A1 (ru)
EC (1) ECSP17011262A (ru)
GT (1) GT201700036A (ru)
IL (1) IL250451A0 (ru)
MX (1) MX358243B (ru)
NI (1) NI201700022A (ru)
PE (1) PE20170667A1 (ru)
PH (1) PH12017500309A1 (ru)
SG (1) SG11201701016WA (ru)
SV (1) SV2017005393A (ru)
TN (1) TN2017000066A1 (ru)
TW (1) TW201619194A (ru)
WO (1) WO2016044436A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
JP2017532953A (ja) * 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
WO2021096829A1 (en) * 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP3498827A1 (en) 2004-05-17 2019-06-19 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
EP2314317A3 (en) * 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2208783A1 (en) * 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
EP2336311A4 (en) 2008-09-25 2012-07-04 Univ Tokyo Nat Univ Corp ANTI-VASA ANTIBODY OF TUNA
SG172427A1 (en) * 2008-12-26 2011-07-28 Univ Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2787073B1 (en) 2011-04-14 2019-03-20 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
AU2012276038B2 (en) * 2011-06-29 2017-08-31 President And Fellows Of Harvard College Compositions and methods for enhancing bioenergetic status in female germ cells
WO2014106235A1 (en) * 2012-12-31 2014-07-03 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
JP2017532953A (ja) * 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Also Published As

Publication number Publication date
CR20170067A (es) 2017-05-10
CA2959179A1 (en) 2016-03-24
US20160311929A1 (en) 2016-10-27
PE20170667A1 (es) 2017-06-06
AU2015317813B2 (en) 2018-04-05
JP2017532953A (ja) 2017-11-09
IL250451A0 (en) 2017-03-30
SG11201701016WA (en) 2017-03-30
SV2017005393A (es) 2017-06-07
US9567404B2 (en) 2017-02-14
MX2017002390A (es) 2017-07-28
AP2017009758A0 (en) 2017-02-28
MX358243B (es) 2018-08-10
DOP2017000050A (es) 2018-04-15
JP2018148915A (ja) 2018-09-27
NI201700022A (es) 2017-05-04
EP3194448A4 (en) 2018-03-14
ECSP17011262A (es) 2017-05-31
TW201619194A (zh) 2016-06-01
GT201700036A (es) 2018-12-19
WO2016044436A3 (en) 2016-06-09
AU2015317813A1 (en) 2017-03-02
BR112017003263A2 (pt) 2017-11-28
WO2016044436A2 (en) 2016-03-24
TN2017000066A1 (en) 2018-07-04
US20180155445A1 (en) 2018-06-07
EP3194448A2 (en) 2017-07-26
KR20170056521A (ko) 2017-05-23
CN106573985A (zh) 2017-04-19
CO2017001724A2 (es) 2017-07-19
US20160075797A1 (en) 2016-03-17
PH12017500309A1 (en) 2017-07-10
US9403913B2 (en) 2016-08-02
US20170107299A1 (en) 2017-04-20
CL2017000402A1 (es) 2017-11-03

Similar Documents

Publication Publication Date Title
EA201790236A1 (ru) Антитела против vasa и способы их получения и использования
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA201492101A1 (ru) Антитела против fcrn
AR106365A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201790307A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
DOP2014000007A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201692495A1 (ru) Биспецифические антитела к il4-il13
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
AR101891A1 (es) Anticuerpos anti-vasa, y métodos de producción y uso de los mismos